The treatment landscape for multiple sclerosis has greatly increased in recent years with the development of new, high-efficacy disease-modifying therapies.

Cladribine tablets are considered one such high-efficacy, immune reconstitution therapy, targeting lymphocytes and sparing innate immune cells in patients with multiple sclerosis.

Offering a clinician’s perspective, this review covers the current treatment landscape and provides practical advice for the management of patients.

The review also discusses the risks associated with COVID-19 and the current recommendations for vaccination.